News Releases

The private label arrangement will bring a new syringeless magnetic resonance (MR) injector to the U.S. 510(k) premarket notification has been submitted to the U.S. Food and Drug Administration

--Leaders in Radiology Will Share Insights on VUEWAY® (gadopiclenol) solution for injection After the First Year of Use in the U.S.--

Radiology residents receive scholarship, research publication in Applied Radiology supplement, and invite to RSNA reception

Bracco’s attendance at RSNA follows FDA approval of Gadopiclenol injection, a novel macrocyclic high-relaxivity gadolinium-based contrast agent which will be commercialized as VUEWAYTM (gadopiclenol) injection by Bracco^{i, ii}

VUEWAY injection is highly stable and shows the highest relaxivity among gadolinium-based contrast agents available for clinical useⁱ

Milestones during the pandemic included U.S. FDA approvals, strides in patient access and enhanced value through solution-driven approaches

Interactive virtual exhibit will offer live expert presentation and Q&A, product demos, and more

Full study results will be presented at the RSNA 2019 Scientific Assembly and Annual Meeting